Vasopressin V1b Receptor | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

13,220 results for “Vasopressin V1b Receptor”

Trials

View all 6587 →

Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder

100 participants · First posted May 25, 2012

Vasopressin and V2 Receptor in Meniere's Disease

135 participants · First posted Jan 23, 2008

V2 Receptor Effects on Fluid Regulation and Performance

10 participants · First posted Mar 12, 2014

Drugs

View all 1479 →

V1b receptor antagonist (HolsboerMaschmeyer)

Vasopressin(Vasostrict)

Manufacturer: Parke davis div warner lambert co

Conditions: Acute Circulatory Failure

C₉₂H₁₃₀N₂₈O₂₄S₄ · Rx

vasopressin V1a receptor antagonists (oral, autism)

Organizations

View all 30 →

Arvinas Estrogen Receptor, Inc.

United States

Arvinas Androgen Receptor, Inc.

United States

Veru Inc

United States

News

View all 5124 →

HMNC Brain Health Completes Patient Randomization in Phase 2b Trial of BH-200 for Major Depressive Disorder

HMNC Brain Health's BH-200 Shows Promising Results in Phase 2 Depression Trial with Genetic Selection Tool

HMNC Brain Health Secures $50 Million Series B Financing and European Partnership with MEDICE for Precision Psychiatry Pipeline

Page 1 of 1322